MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa 15-10-2023, 20:03

Mavenir’s Network Intelligence as a Service (NIaaS) Wins the Advancing Artificial Intelligence Award at the 2024 Glotels 27-11-2024, 19:06

eXp Realty Enters Türkiye, Marking Second Global Expansion in Just Four Weeks 17-04-2025, 20:16